Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment
INTRODUCTION
Mast cells (MCs) are found in most organs and tissues of the body and are present in highest numbers in locations that interface with the environment, such as the skin, the lung and the gastrointestinal tract. 1 It is estimated that if all MCs in the human body were assembled in one organ, their mass would equal that of the spleen. 2 Mast cells are derived from CD34 progenitor cells in the bone marrow. 3 Although most cells descending from progenitors in the bone marrow differentiate into mature cells before leaving the bone marrow, MCs leave as morphologically unidentifiable progenitors and differentiate into phenotypically identifiable MCs only after they infiltrate connective or mucosal tissue. [4] [5] [6] In addition, fully granulated
MCs in well-differentiated mast cell tumours (MCTs) can undergo mitosis, indicating that fully differentiated MCs have the potential to proliferate. 7 In rodents, formalin-resistant connective tissue type MCs (CTMC), and formalin-sensitive mucosal type MCs (MMC) have been identified. 8, 9 Canine MC heterogeneity based on formalin sensitivity has been identified in the skin, 10, 11 trachea, lung, intestine and in MCTs. 11, 12 However, the classification used in rodents is not found to be appropriate for subtyping canine MCs. 13, 14 Instead, three subtypes exist in dogs based on their content of the proteases, chymase and tryptase, which are present in both normal and neoplastic MCs.
In addition to genetic mutations, some authors have suggested that chronic cutaneous inflammation may play a role in MCT development. 60 However, only rare cases of MCTs associated with chronic dermatitis, scar formation or the application of skin irritants have been documented. 61, 62 Other studies have suggested a possible viral cause and MCTs have been transplanted to very young or immunocompromised laboratory dogs through tumour cells and cell extracts but unequivocal evidence of a viral aetiology is lacking.
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HISTORY AND CLINICAL PRESENTATION
The vast majority of canine MCT occur in the dermis and subcutaneous tissue. In addition, they are occasionally reported in extracutaneous sites, including the conjunctiva, salivary gland, nasopharynx, larynx, oral cavity, gastrointestinal tract, urethra and spine. 66 Visceral MCTs (disseminated or systemic mastocytosis) are almost always preceded by an undifferentiated primary cutaneous tumour, and primary MC leukaemia is extremely rare.
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Incidence Dogs have an unique risk of developing cutaneous MCTs 68 which account for 7% to 21% of all canine skin tumours. [69] [70] [71] [72] [73] [74] [75] [76] Furthermore, MCTs are reported to be the most common canine skin tumour submitted for histology and diagnosed in veterinary teaching hospital populations [68] [69] [70] 72, 77 with an incidence of 129/100,000 dogs per year in one UK study of insured dogs. 78 
Breed predisposition
Breeds found to be predisposed to develop MCTs include boxers, Boston terriers, bull terriers, bullmastiffs, cocker spaniels, Staffordshire terriers, fox terriers, English bulldogs, dachshunds, labrador retrievers, golden retrievers, beagles, pugs, schnauzers, shar-peis, Rhodesian ridgebacks, Weimaraners, and Australian cattle dogs. 68, 70, 72, [79] [80] [81] [82] In one study, boxers and Boston terriers represented more than 50% of dogs with MCTs and the relative risk of developing MCTs was found to be 16.7 for boxers and 8.0 for Boston terriers. 69 The increased incidence in these two breeds may be related to their common bulldog ancestry. 80 Site predilection has also been reported for various breeds: hind limbs and multiple lesions in boxers and pugs, hind limbs in Boston terriers and American Staffordshire Terriers, the tail in Rhodesian ridgebacks, multiple lesions in Weimaraners and golden retrievers, and the head and hind limbs in English setters.
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Gender
Most studies report no gender predilection 66, 69, [80] [81] [82] 84 or association between gender and survival, 81 with the exception of one European study in which female dogs were found to have a more favourable prognosis with chemotherapy than their male counterparts. 85 It is, therefore, unclear whether sex hormones may have an impact on tumour behaviour. 66 
Age
The mean age of dogs at presentation is between 7.5 and 9 years, 60, 66, 68, 69, 73, 81, 82, 84, [86] [87] [88] [89] although MCTs are occasionally found in dogs as young as 4 to 6 months of age. 73, 90, 91 Tumour site and gross appearance Dogs with cutaneous MCTs are most frequently presented for the evaluation of a cutaneous mass, and only rarely for clinical signs related to the release of mediators from MC granules. 67, 68, 74 Cutaneous MCTs are most common on the trunk (50% -60%), followed by the extremities (25% -40%), and the head and neck (10%). [68] [69] [70] 92, 93 The scrotum, perineum, back and tail are less commonly affected. 79 In general, a greater number of tumours affect the posterior part of the body (hind limbs, perineum and prepuce). 67, 71 The gross appearance of MCTs varies widely and can mimic other cutaneous tumours and non-neoplastic conditions ( Fig. 1 ). MCTs must, therefore, be considered in the differential diagnosis of any skin nodule. 86 The gross appearance of MCTs correlates to some extent with histological grade. 92 Low-grade, well-differentiated MCTs tend to present as a solitary, rubbery, slowly growing nodule with 1 to 4 cm in diameter, which are often present for over 6 months prior to diagnosis. 66, 72 These may be alopecic but are typically non-ulcerated. Another form of MCTs are subcutaneous tumours that may be soft and fleshy on palpation and are often grossly misdiagnosed as lipomas. 66 Undifferentiated MCTs tend to grow rapidly, ulcerate, cause considerable irritation and may give rise to small satellite nodules in the surrounding tissues. 66, 72 Most MCTs are not pigmented, but occasionally erythematous and hyperpigmented nodules are found. 68 The surrounding tissue may be inflamed and oedematous 66 and can present urticarial swelling or diffuse areas of oedema and inflammation resembling cellulitis. 86 Lesions on the distal extremities, lips and in the inguinal area may present as poorly defined areas of swelling or mimic acral lick dermatitis. 29, 61, 94 In addition, diffuse MCTs can produce gross distension and deformation of the hind limbs in shar peis. 95, 96 Palpation of MCTs occasionally causes degranulation with release of histamine and other vasoactive substances that results in local vasodilatation, oedema and erythema, also known as Darier's sign. 66, 68, 86 Likewise, manipulation of visceral MCTs can cause vomiting and abdominal pain. 60 
Multiple MCTs
In most dogs, MCT presents as a single cutaneous tumour but between 5% and 25% of dogs are affected with multiple skin tumours which may occur synchronously or sequentially. 29, 61, 66, 68, 71, 73, 83, 86, 89, 97, 98 Breeds reported to be more frequently affected by multiple tumours include boxers, pugs, Weimaraners, golden retrievers and shar peis. 79, 83 A case of multiple pruritic MCTs that spontaneously regressed was also reported in a 3-week-old jack russel terrier. 90 However, this may have been a hyperplastic MC proliferation 29, 66, 68 or possibly a condition akin to urticaria pigmentosa in humans. 86 
Paraneoplastic syndromes and complications of granule release
Complications related to the release of the bioactive substances in MC granules (histamine, heparin, eosinophilic chemotactic factor and proteolytic enzymes) occur in up to one half of dogs with MCTs. 74, 97 Delayed wound healing after surgical excision is a common problem attributed to proteolytic enzymes and vasoactive amines released by the tumour. 66, 67, 87 Studies in mice suggest that released histamine binds to H 1 and H 2 receptors on macrophages causing the release of fibroblastic suppressor factor that decreases normal fibroplasia and delays wound healing. 66 Furthermore, histamine and human mast cell leukaemia lysates have been shown to reduce keratinocyte proliferation and thus inhibit wound epithelialisation. 66 Local haemorrhage is frequently encountered during surgical excision, fine-needle aspiration and excessive manipulation of MCTs 64 and is likely due to coagulation defects caused by released heparin. 64, 66, 67, 99, 100 Indeed, prolonged coagulation time of blood taken from or around MCTs is frequently observed 66 although prolongation of coagulation times from venous blood samples are observed in a small minority of patients. 99 Since haemorrhage can be a serious complication of surgery, clinicians should anticipate local bleeding and try to avoid excessive tumour manipulation during biopsy or excision. 66, 64 Fortunately, uncontrollable bleeding is rarely a problem during the surgical excision of MCTs.
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Gastrointestinal ulceration due to MCTs can cause anorexia, vomiting, haematochezia, melaena, anaemia, abdominal pain and, in some cases, intestinal perforation and peritonitis. 66, 69, 84, 87 Such complications are usually restricted to aggressive high-grade or extensive MCTs. 66, 69, 87 Nevertheless, gastrointestinal ulceration is found in about 35% to 83% of dogs with MCT at necropsy examination. 101 The pathogenesis of gastrointestinal ulceration associated with MCTs appears to be caused by a combination of vascular damage, excessive gastric acid production through stimulation of H 2 receptors on parietal cells and hypermotility. 66, 64, 102 Malignant MCs contain 25 to 50 times more histamine than normal MCs 103 and dogs with MCT have significantly higher plasma histamine and lower gastrin levels than normal dogs. 102 The lower gastrin levels are thought to be the result of negative feedback from increased gastric acidity. 83, 110 MCTs in labrador retrievers are also frequently more aggressive than in other breeds.
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Growth rate and size
The growth rate of MCTs (tumour volume divided by the duration of time the tumour has been present) is a significant prognostic factor. 92 Indeed, MCTs that remain localised and are present for prolonged periods (months or years) without significant change are usually benign, and those present for over 7 months carry a favourable prognosis. 92 Furthermore, large tumours may be associated with a poorer prognosis. 89 
Gender
Only one study reported gender-associated differences in prognosis with female dogs doing better than males following treatment of MCTs with chemotherapy. 85 
Clinical stage
A clinical stage of 0 or I (Table 1 ) carries a better prognosis than any higher stage disease 85, 92, 109 and metastasis at the time of initial diagnosis significantly shortens survival. 93 However recent reports show that stage II MCTs can be treated successfully resulting in comparable disease free survival time to stage 0 disease. 111, 112 In addition, it has been shown that dogs with multiple MCTs treated surgically had a low metastatic rate and a good prognosis for a long term survival. 113 Postsurgical recurrence is thought to be associated with a poorer prognosis. 60, 105 These data suggest that with appropriate therapy, the clinical stage has minor prognostic value.
Metastatic disease
MCTs are always considered potentially malignant, 29, 67 but the true metastatic potential of MCTs is unknown. 66 Well-differentiated tumours have a metastatic rate of less than 10%, and intermediate tumours are considered low to moderate in metastatic potential. 66, 108 In addition to greater local infiltration, undifferentiated tumours have a much higher metastatic rate, ranging from 55% to 96%. 67, 92, 114 Differences in reported metastatic rates for different histological grades may be in part due to the somewhat subjective system of grading. 66 Most MCTs first metastasize to local lymph nodes and then to the spleen (46%), liver (41%) or other visceral organs. 29, 66, 73, 74 Lung involvement is very uncommon. 66 Neoplastic MCs may be observed in the bone marrow and in the peripheral blood in cases of widespread systemic dissemination. 66 The 116 However, granules in some MCTs stain poorly with rapid stains unless the slide is immersed for several minutes in the alcohol fixative. 66, 103, 116 In addition, poorly granulated mast cells may be difficult to recognise (Fig. 3) . 66, 68, 74 Although grading of MCTs requires histological evaluation, cell morphology and staining characteristics observed on cytological preparations give an indication about the degree of differentiation. 68, 103 Anaplastic or high-grade tumours normally yield a highly cellular sample with cells having a low number of cytoplasmatic granules, irregular nuclei and increased pleomorphism and mitotic figures. 74, 117 In some cases, poorly-granulated cells of anaplastic tumours may be more easily recognized in cytological smears and imprints than in histological sections due to the greater resolution of granules in cytology. 103 
Further diagnostic workup
The extent of ancillary diagnostic workup and staging following a cytological diagnosis of MCT has recently be re-evaluated and depends on the presence or absence of negative prognostic factors 60, 66 as illustrated by Thamm and Vail (Fig. 4) . 66 The minimum workup in cases requiring presurgical staging consists in FNA of the draining lymph nodes even if they are normal in size 107 and abdominal ultrasound. 60, 66 Evaluation of the sublumbar lymph nodes may require ultrasonography or other imaging techniques. 67 If enlargement of the sublumbar nodes is present, metastatic disease should be presumed. 67 The interpretation of lymph node cytology is not always easy because MCs can be found in lymph node aspirates in normal animals. 68, 87 The WHO guidelines suggesting that cytological specimens need only be evaluated for the presence or absence of MCs may, therefore, lead to an incorrect diagnosis of metastasis. 118 Current recommendations are that metastasis to a lymph node should be diagnosed by cytology if MCs represent more than 3% of the cell population in the aspirate. 87 However, even with this criterion, up to 25% of normal dogs would be diagnosed with a metastatic MCT and evaluation of the degree of cytological differentiation and clustering or aggregation of cells, should also be considered in the final cytological diagnosis of metastatic disease. 66, 68, 87 In suspicious cases, surgical extirpation of a lymph node and histological assessment should be considered. 66 Knowledge of the extent of gross MCT margins allows more appropriate planning for surgery or radiotherapy and the exact extent of local tumour margins was upgraded in 19% of cases with ultrasound and in 65% of cases with computed tomography in one study. 119 However, it has to be considered that such examinations add additional costs and, therefore, may only be justified if the tumour location does not allow wide excisional margins. 66, 118 Thoracic radiographs are seldom indicated as MCTs very rarely metastasize to the lungs.
Moreover, when lung metastasis does occur, diffuse interstitial infiltrates are more common than discrete nodules. 66, 103 Nevertheless, thoracic radiographs are reasonable in older patients to rule out an unrelated disease that may complicate anaesthesia if an expensive or invasive procedure is necessary. 66 Aspiration cytology of sonographically suspicious lesions in the liver or spleen is recommended but interpretation can be complicated by the presence of non-malignant MCs in these organs in normal dogs. 66 The validity of screening buffy coat smears in dogs with cutaneous MCTs for possible systemic involvement has been disputed because mastocytaemia is more frequently observed in dogs with inflammatory conditions than MCT. 66, 120 Moreover, the visceral form of MCT constitutes a small minority of all canine cases and many authors have abandoned the routine examination of buffy coat smears, reserving this diagnostic procedure for selected cases. 60, 66, 87, 97 Equally, bone marrow aspiration is no longer recommended in the routine staging of canine MCT. 66 The vast majority of dogs with cutaneous MCTs do not have circulating MCs or evidence of bone marrow infiltration 66, 87 and involvement of peripheral blood or bone marrow is unlikely in the absence of disease in the regional lymph nodes or abdominal organs. 66, 87 Moreover, visceral MCT carries a very grave prognosis and the additional presence or absence of neoplastic MCs in blood or bone marrow rarely alters treatment decisions.
Clinical staging
The WHO clinical staging system for MCTs 71 ( 87 A preliminary study suggests that some subcutaneous
MCTs even have a slightly better long-term prognosis than higher grade dermal variants. 123 As a consequence of the above mentioned weaknesses, a significant number of dogs are probably treated more aggressively than necessary. 87 Therefore, it is necessary to update the WHO clinical staging system for cutaneous MCTs but so far, no consensus exists over the best staging procedure for canine MCTs and various authors use their own systems.
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Histological findings and staining properties
Although FNA cytology is convenient for diagnosis, it does not provide a histological grade and excisional samples should be submitted for histological grading and margin assessment. 29, 66, 68, 87, 97 The diagnosis of MCTs is straightforward in most cases. They present as nonencapsulated dermal and/or subcutaneous infiltrative growing masses composed of round cells arranged in densely packed cords or loose sheets. Cellular morphology depends on the degree of differentiation but most neoplastic MCs have a distinct cell membrane, a central round nucleus and variable numbers of cytoplasmic granules that stain light-grey blue with haematoxylin and eosin or purple with metachromatic stains such as toluidine blue.
The collagenous stroma varies from scant to abundant, and may appear oedematous or hyalinised.
Variable numbers of eosinophils are either dispersed throughout the neoplastic mass or form aggregates.
Marked deposition of mucin and perivascular hyalinization may be seen in response to the eosinophilic infiltration, and eosinophilic vasculitis may be present. Foci of marked eosinophilic degranulation may entrap brightly eosinophilic collagen bundles to form flame figures.
Well differentiated MCTs ( (Table 2) , however, in the authors` experience and of others, tumours with the above described morphology may also invade the subcutaneous tissue. 29, 124 Intermediate-grade MCTs ( Cellular density and morphology varies significantly between grades, and poorly differentiated
MCTs can be confused with other round cell tumours. Thus, numerous attempts have been undertaken to apply histochemical and immunohistochemical stains for a definitive diagnosis of poorly differentiated
MCTs. In one study that examined the use of the histochemical stains, alcian blue pH 2.5, azure and eosin, Giemsa, Luna's method for MCs, periodic acid-Schiff reaction, safranin O, toluidine blue, Torren's method, Unna's method, chloracetate esterase, and the affinity stains, avidin peroxidase, wheat germ agglutinin, and concavalin-A agglutinin, as well as immunohistochemical stains with CD68, none of the staining techniques was found to be ideal. 126 Based on a previous publication and our own experience, immunohistochemistry with antitrypase antibodies or histochemical stains for chymase activity may, however, be helpful in the diagnosis of poorly granulated MCTs. 127 Indeed, 7/7 (100%) grade I, 6/7 (85.7%) grade II, and 3/7 (42.9%) grade III tumours were diagnosed as MCTs based on these stains. 127 In addition, MCTs are positive for the common leukocyte marker, CD45, and retain variable expression of the leukocyte antigens, CD45RA and CD18. 29 As discussed earlier, MCTs also express KIT, but none of these antigens is specific for MCTs. Very recently, the production and characterization of mouse monoclonal antibodies specific for canine MCTs, were reported. 37 In this study, one of the antibodies 132, 133 This is mainly due to the fact that histological grading is based on the use of subjective parameters such as invasiveness, cellularity, cellular morphology, and mitotic index. [132] [133] [134] [135] As a result, various attempts have been undertaken to use more objective methods to assess the grade of MCTs.
Grading based on morphology
Nuclear morphometry has been shown to be significantly associated with histological grading of various tumours in humans and animals. [136] [137] [138] [139] [140] [141] Two groups investigated nuclear morphological features as possible indicators of histological grade in canine MCTs. 135, 142 These groups demonstrated significant differences between grades I and III and grades II and III for mean nuclear area, nuclear diameter and nuclear perimeter but differences between grades I and II were not significant ( Table 3 ). The mitotic index (MI) has been shown to be a strong predictor of outcome for a variety of human and canine cancers 143, 144 and several studies have demonstrated a prognostic value of MI in canine MCTs (Table   3) . 124, 134, 135, 142, [145] [146] [147] Moreover, in one recent study, the median survival for dogs with a MI ≤ 5 was significantly longer (70 months) than for those with a MI >5 (2 months), regardless of histological grade. 147 However, in the authors' experience, MI may be difficult to assess in highly granulated MCTs.
The results of the studies undertaken to give a prognostic indicator with different morphological features and morphometric variables are summarized in Table 3 . In conclusion, morphological features are useful in predicting MCT behaviour but predicting prognosis in intermediate-grade MCTs still remains problematic. The MI seems to be a strong predictor for the prognosis with regard to survival time.
However, in the two studies in which the impact of MI on the rate of recurrence was investigated, the results are controversial. 134, 146 Nevertheless, the MI is an objective measure and may help to limit interobserver variation in the histological evaluation of MCTs. A problem that remains to this date is that the various studies used different cut-off values and thus the data are still difficult to apply in a diagnostic setting.
Grading based on proliferation markers
Uncontrolled cellular proliferation is a hallmark of cancer and, as such, measures of cellular proliferation have been extensively used in an attempt to predict behaviour in neoplastic disease. 47, 124, 126, 131, 133, 138, 143, [152] [153] [154] [155] [156] [157] [158] In veterinary medicine, the most commonly used methods include staining for argyrophilic nucleolar organizer regions (AgNORs), immunohistochemistry proliferating cell nuclear antigen (PCNA) and for Ki67, all of which have been investigated in canine MCTs (Table 3) . 148, 149 AgNORs are areas in the nucleus that are associated with proteins, such as nucleolin and nucleoplasmin substructures, involved in ribosomal RNA transcription. 150 They are widely used as a marker of tumour kinetics and tumour metabolic activity. AgNORs bind silver molecules and can be visualised by light microscopy using a silver-based histochemical stain. 151 The quantity of AgNORs per nucleus has been shown to be proportional to the rate of cell proliferation or cell doubling time in vitro [152] [153] [154] and the rate of tumour growth in vivo. [155] [156] [157] A number of studies have shown that higher AgNOR counts in MCTs are associated with increased mortality, local recurrence and metastasis. 47, 124, 134, 158 PCNA is a protein that interacts with DNA polymerases, acting as an auxiliary factor for DNA replication and repair. 159, 160, 161 Although PCNA has an extended half-life and is involved in multiple nuclear functions, maximal PCNA expression is commonly seen in the synthesis phase of the cell cycle (S-phase). 49, 162, 163 Two studies have shown an association between PCNA expression and increased mortality in canine MCTs. 47, 134 However, only one of these two studies found an association between high PCNA expression and recurring or metastatic tumours 47, 134 and other studies found no correlation between PCNA expression and prognosis. 128, 158 Furthermore, PCNA expression has not been found to be a prognostic marker independent of the histological grade in any study. 47, 126, 128, 134, 158 Ki67 is a nuclear protein that is expressed in all active phases of the cell cycle but is not present in noncycling cells. 164, 165 The relative number of Ki67-positive cells is used to determine the proliferation index or the relative number of cells actively involved in the cell cycle (growth fraction). 148, 149, 164, 165 A high Ki67 expression in MCTs has been shown to be associated with increased mortality, the rate of local recurrence and metastasis. 47, 128, 158 In addition, Ki67 was found to be better than AgNORs for identifying MCTs associated with decreased survival, although AgNORs were better markers for identifying MCTs with a decreased disease-free interval. 47 Importantly, Ki67 has been shown to be a prognostic factor that is independent of histological grade. 47, 158 Thus, Ki67 immunohistochemistry can be used as an objective prognostic marker in MCTs.
KIT expression was found to be significantly correlated to histological grade, Ki67 expression, AgNORs and tumoural necrosis in one study. 166 Furthermore, significant correlations were also established between Ki67 and AgNORs with histological grade, tumour necrosis and epidermal ulceration. In this study, no differences were observed between focal and diffuse cytoplasmic KIT staining and histological variables. 166 The latter finding is in contrast to results presented in other studies, which demonstrated an association between aberrant cytoplasmic KIT expression and either increased proliferation index, the presence of c-kit mutations, increased local recurrence or decreased survival. [45] [46] [47] 51 Tumour angiogenesis plays a key role in tumour growth and metastasis 167, 168 and the prognostic role of intratumoural microvessel density (IMVD) has been demonstrated for canine mammary tumours and squamous cell carcinoma. [169] [170] [171] [172] IMVD has also been evaluated by immunohistochemical staining of canine MCTs for the endothelial marker factor VIII (von Willebrand's factor)-related antigen, and found to be associated with tumour recurrence and mortality. 145 Abnormal DNA content (aneuploidy) was investigated in 40 canine MCTs using flow cytometry. 173 In this study, over 70% of the MCTs were diploid. When comparing diploid and aneuploid tumours, a significant difference was found between clinical stage I versus non-stage I tumours but only a trend towards shorter survival was found in dogs with aneuploid tumours. 173 Mutation of the p53 gene is the most common genetic alteration known to occur in human cancer. 174 The product of the p53 tumour-suppressor gene is a nuclear transcription factor whose functions include cell cycle arrest in cells with damaged DNA, induction of transcription of DNA repair enzymes, and the induction of apoptosis in cells that have sustained irreparable genetic damage. [174] [175] [176] [177] Two studies investigated p53 immunoreactivity in canine MCTs but neither could show an association with survival or tumour recurrence. 129, 178 Similarly, expression of survivin, an inhibitor of apoptosis, was investigated in canine MCTs but no association was found between survivin expression and survival. 158 Matrix metalloproteinases have been associated with tumour invasion and metastasis in a variety of neoplasms in humans and animals. [179] [180] [181] Matrix metalloproteinases 2 and 9 are secreted by canine MCTs and activated by exocytosed chymase. 68, 204 Their expression in MCs is regulated by KIT ligand and tumour growth factor-β. 182, 183 Moreover, undifferentiated MCTs were found to express higher levels of these enzymes than intermediate-grade MCTs. 184 Vascular endothelial growth factor (VEGF) has also been investigated as a mediator of diseaserelated angiogenesis and potential autocrine growth regulator of neoplastic cells. [185] [186] [187] [188] Although canine
MCTs were found to express both VEGF and VEGF receptors,VEGF was not found to be a growth regulator in canine MCTs. 189 The results of all the studies investigating proliferation markers as prognostic factors are summarized in Table 3 . From these studies it can be concluded that Ki67 and AgNORs seem to be the most valuable factors predicting MCT behaviour. Of these, the Ki67 index is much easier to assess and is a factor predictive of prognosis independent of Patnaik grading. However, the various studies investigating Ki67 have used different cut-off values to differentiate between tumours that are likely to have a favourable prognosis and those that are likely to have a poor prognosis, making practical widespread application of a Ki67 index difficult. Thus, the MI which can be assessed much easier in a diagnostic setting seems to be equally valuable. 89, 93, [190] [191] [192] [193] The historically suggested 3cm surgical margins 194 for resection of canine MCTs have recently been replaced by studies demonstrating that a 2cm lateral margin and a deep margin of one fascial plane is sufficient for the complete excision of most grade I and II MCTs. 191, 195 For cases with clean excision of stage I well-differentiated to intermediate grade tumours a rigorous re-evaluation schedule and close monitoring for recurrence rather than adjuvant therapy is recommended (Fig. 6) . 66 Presurgical consolidation and reduction of tumour burden with prednisone can be realized in 70% and will improve the likelihood of obtaining complete resection margins. 121, 196 In a recent report of incompletely excised grade II MCTs, 23% of all tumours recurred. 193 Adjuvant therapy with radiation is known to improve local tumour control and the incorporation of further prognostic factors, such as Ki67 scores or MI may help to select patients that are most likely to profit from ancillary local therapy. 147, 193 Tumours on the extremities, for example, can almost always be controlled with amputations, but the routine use of adjuvant radiotherapy and marginal surgical excision yields high local control rates as well as excellent functional outcome. Incompletely excised intermediate grade MCTs in all locations, treated with adjuvant radiation therapy result in a 1-to 2-year disease free interval (DFI) in 81% to 95% of cases. 106, 109, 192, 197, 198 In contrast to "high-risk" tumours (e.g. tumours occurring at mucocutaneous junctions, grade II stage II or grade III MCTs), 112, [199] [200] [201] prophylactic irradiation of cytological negative lymph nodes has not been found to increase overall survival. 192 
TREATMENT OF CANINE CUTANEOUS MAST CELL TUMOURS
Well-differentiated to intermediate grade MCTs with lymph node involvement
For dogs with well-differentiated to intermediate grade, solitary cutaneous tumours and metastasis to regional lymph node (stage II), several approaches have been described. Good outcomes with a median DFI of 40.6 months have been found for combined therapy with surgery and irradiation. 190 While adjuvant chemotherapy is also possible, the need for systemic therapy in these cases is questionable.
High grade or high-risk MCTs
The median survival for patients with high-risk tumours (e.g. mucocutaneous, gingival, perineal, prepucial, nail bed), grade II stage II or grade III MCTs varies between 3.5 and 20 months after surgical excision alone and combination of surgery and radiation therapy, respectively. 81, 134, 202, 203 In spite of acceptable results with surgery and radiotherapy, 202 the majority of veterinary oncologists feel that local therapy alone is insufficient for optimal control of high-grade MCTs. 112, [199] [200] [201] The outcome of such cases treated with a multimodal approach aiming at adequate local control and additional use of prednisone / vinblastine chemotherapy yielded superior results with a DFI of 45 months and 65% of patients alive at 3 years (Fig. 8) . 112, [199] [200] [201] When wide surgical excision is not possible, cytoreductive surgery or palliative radiation using coarse fractions of 6-8 Gy with total doses of 24-36 Gy, followed by systemic chemotherapy with prednisone / vinblastine may be considered. 66 As adequate local control is practically impossible in these cases, prognosis is only fair with median survival of approximately 5 months. 105 
Metastatic or recurrent MCTs
A large number of patients not cured of their disease during initial treatment will develop local and/or loco-regional failure (5% to 23%) in the absence of distant metastatic disease. 118, 131, 193 In such cases, reevaluation with staging is necessary and treatment should follow similar rules as for primary disease.
Systemic treatment with vinblastine / prednisone in one study involving mostly incompletely or marginally resected intermediate grade MCTs yielded low rates of local recurrence (3.7%) and metastatic disease (15%). 204 In addition, up to 44% of dogs cured of a previous MCT, will develop de novo MCTs which require individual staging and grading. 89, [190] [191] [192] [193] In cases of visceral metastatic disease, any attempt of local control should be accompanied by systemic therapy consisting in cytotoxic chemotherapy and ancillary therapy aiming at controlling or reducing the systemic effects of release of MCT granules. The recommended choice of chemotherapy is vinblastine / prednisone, 105 or the combination protocol using vinblastine / cyclophoshpamide / prednisone. 205 CCNU (lomustine) has also been shown to result in measurable, albeit short lived response (2.6-5 months) in 42% to 47% of macroscopic MCT. 206 Many oncologists are using a protocol that incorporates vinblastine / CCNU / prednisone (Table 4) , however, results on the outcome of this protocol in peer reviewed literature is still pending.
External beam radiation therapy
The use of external beam radiation therapy is recommended for postoperative residuals, microscopic or subclinical disease, if further resection is not possible. Furthermore, radiation therapy can also be applied pre-operatively in order to reduce tumor size prior to surgery. 207 Radiation therapy at low doses of [40] [41] [42] [43] [44] [45] Gy or hypofractionated protocols yield a 1-year tumour control rate of about 44% to 78% for macroscopic tumours. 109, 121, 208 Control rates and duration may be improved with the application of higher total doses of up to 57 Gy, but the use of radiation as a single modality for MCT should be reserved for nonresectable locations. 207 Combined treatment of radiation therapy and surgery greatly improves tumour control, especially in cases where surgery alone is incapable of controlling the disease due to functional or cosmetic constraints. 207 DFIs of 94% at 1 year and 80% at 5 years have been reported following about 54
Gy radiation of intermediate grade, stage 0 disease. 197, 198 As previously mentioned, prophylactic irradiation of the regional lymph node underlies debate, but some institutions routinely treat negative lymph nodes with 48 Gy (16 fractions) and positive nodes with 54 Gy (19 fractions). 190, 198 For locoregional disease with systemic spread, palliative radiation can be considered as an (additional) option for local palliation of disease.
Generally, a minimum of a 3cm margin of normal appearing skin is included in the radiation field. For lymph nodes, the prescribed radiation fields are generally succinct to include the node and about 1cm margins. For definitive therapy, total doses of 48-57 Gy are described in 15-19 fractions. 207 
Chemotherapy
The use of chemotherapy in the management of canine cutaneous MCTs primarily aims at the treatment of disseminated, non-resectable or high-grade tumours and may be considered for microscopic disease, if radiation therapy -the primary choice for microscopic residual disease -is not feasible. Various chemotherapeutic drugs and protocols have been evaluated in macroscopic canine MCT 201, 205, [209] [210] [211] [212] [213] and several studies have used chemotherapy as adjuvant after surgical removal and / or irradiation of the tumour. 112, [199] [200] [201] 205, 209 The response of cutaneous MCTs to prednisone as a single agent, 214 prior to surgical excision or irradiation (neoadjuvant), 121, 196 and in combination with chemotherapeutic agents such as vinblastine 112, [199] [200] [201] , vinblastine / cyclophosphamide 205, 209 or cyclophosphamide / vincristine / hydroxyurea 210 was described in several reports.
The response rate to single agent chemotherapy for measurable disease was reported in four peerreviewed publications and ranges from 7% to 13% for the vinca alkaloids (vincristine: 7%, vinblastine:
11.8% and vinorelbine: 13%) to 44% for the alkylating agent CCNU. [211] [212] [213] 215 Only the duration of response to CCNU monotherapy was described and found to be short-lived with 2.6 months duration. 213 While the overall objective response to single agent systemic prednisone therapy has been observed to be 20% to 70%, there was a lack of durable efficacy in the only controlled clinical trial. 214 In the other two studies describing the response of cutaneous MCTs to oral prednisone treatment, response was evaluated when the drug was used as neoadjuvant in order to facilitate combined treatment such as surgery or radiation therapy. 121, 196 However, the inclusion of prednisone into chemotherapeutical protocols has produced overall response rates of 47% to 64% 201, 205, 210 and the 47% overall response found for the combined therapy of vinblastine and prednisone and the 44% response rate to CCNU monotherapy has todate directed these protocols as standard of care in the management of this disease. While a pilot study using a cyclophosphamide / vinblastine / prednisone combination demonstrated a 78% response rate in dogs with measurable metastatic MCT, 209 the efficacy of this protocol combining vinca alkaloid with an alkylating agent and prednisone has been recently confirmed with a measurable 64%response of comparable duration to previously described combined protocols. 205 For combined therapy aiming at adequate local control of the primary and regional metastatic tumour with surgery and/or radiation therapy, the several chemotherapy protocols have shown to increase the DFI up to 43.5 months (Table 4) . 112, 199, 201, 205 Trials including CCNU as part of combined chemotherapeutical protocols for cases with or without adequate local control of the primary tumour are underway with results presented at scientific meetings, but confirmed peer-reviewed results are still pending.
The prevalence of toxicity was described to be up to 26% for combined therapy of vinblastine / prednisone, with 5% to 6.5% of moderate to severe toxicities including vomiting and / or neutropenia with fever necessitating hospitalisation or discontinuation of treatment. 112, 199, 201 In the study using vinblastine / cyclophosphamide / prednisolone, the toxicities were described to be mild with 11.4% to 14.2% mild myelosuppressive and 2.8% moderate gastrointestinal toxicity. 205 The acute dose-limiting neutropenia after administration of CCNU was found to be moderate to severe in up to 41%. 213 CCNU has also been associated with cumulative, dose related chronic hepatotoxicity and other toxicities such as fever, ascites, pleural effusion.
213,216
Medical treatment of systemic signs
For clinically symptomatic problems related to excessive histamine release, a combination of H 1 and H 2 blocker therapy is recommended. Recommendations include the use of these agents for systemic or local signs (Darier's sign), cytoreductive surgery (where the tumour is likely to be manipulated) and where degranulation is expected to occur in situ (treatment of macroscopic disease with radiation or chemotherapy) (Table 5 ).
66,121
Other treatment modalities
Other local therapies, including intralesional brachytherapy, 217 photodynamic therapy 218 and the use of intralesional corticosteroids or deionized water 178,219-221 have been described, but thorough investigation of these treatments in large patient populations is lacking. In addition, these treatment modalities negate the possibility to assess local tumour control by histological evaluation of margins.
Several drugs targeting the KIT tyrosine kinase receptor are being tested in vitro 59 and some clinical response in dogs with MCTs has already been noted in a phase I study of a tyrosine kinase inhibitor. 222 The use of biological response modifiers (i.e. agents that modify the relationship between the tumour and host) have been studied for years in veterinary medicine. The approach for treatment of cutaneous canine MCT was made by using the immunomodulatory and antitumour effect of LDI-100, a preparation containing human chorionic gonadotropin (HCG) and bacillus Calmette-Guerin (BCG). The 28.6% clinical responses were comparable to single-agent vinblastine chemotherapy, however, with significantly less side effects.
222
CONCLUSIONS
Dogs have a unique risk to develop cutaneous MCTs, which account for up to 21% of all skin tumours. 
